ÂÜÀòÂÒÂ×

Pete has more than 25 years of experience in both drug discovery across the pharmaceutical industry and in building early-stage therapeutics companies. Prior to joining Epidarex, Pete was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the UK. In this role, he had strategic and operational oversight for the respiratory portfolio from target discovery through to proof-of-concept trials in the clinic.

Pete is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. In this capacity, he led target discovery, validation and early drug discovery programs across a wide range of therapeutic areas including oncology, neuroscience, regenerative medicine, autoimmunity and inflammation. The approaches used have been extensively published in Nature and Cell.

Pete’s experience from senior transatlantic industry roles to dealing with the day-to-day complexities of building venture-backed start-ups, ensures he is well qualified to join the BIA’s Board. He has an extensive global network of Pharma and Biotech contacts. Pete’s background in successfully funding innovative therapeutics start-ups is particularly relevant to the BIA’s goal of further establishing our industry as a global hub of drug discovery and development.